Two New Studies Profile Prognostic Factors for Breast Cancer
Two new studies provide insight into the use of new and standard prognostic factors for women with breast cancer. The first, conducted by Dr. Massimo Cristofanilli and colleagues at several prominent U.S. cancer research centers, confirms the long-held hypothesis that the number of cancer cells in the blood are a direct indicator of disease severity. The results are published in the August 19 New England Journal of Medicine.
This research was performed using a new test - the CellSearch System - which uses antibody-coated magnetic beads followed by fluorescently labeled monoclonal antibodies to distinguish cancerous epithelial cells from leukocytes in a blood sample. The test was developed by the research sponsor, Immunicon Corp. Read more
A Vital Connection to the Cancer Community
One of the most effective ways in which NCI interacts with the cancer community is through our advisory boards. Next week, for instance, the National Cancer Advisory Board (NCAB) will meet for the third time this year. Among the advisory boards and committees to NCI, the NCAB plays a unique role. The NCAB advises both NCI leadership and the secretary of the Department of Health and Human Services with regard to the Institute's strategic plan and its intramural and extramural research activities. The committee's 18 members are appointed by the President.
The NCAB also is distinct from other NCI advisory boards in that it provides secondary peer review of all grant applications to NCI over $50,000. This is a critical responsibility that ensures the NCAB is an active participant in guiding the direction of cancer research. Read more